Thomas Theuringer News Today

ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% re

Venlo, the Netherlands, May 29, 2024 -- QIAGEN today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for...

Media Release QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance ...

Venlo, the Netherlands, April 03, 2024 -- QIAGEN N.V. today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new...

Venlo, the Netherlands, March 25, 2024 -- QIAGEN today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used...

Venlo, the Netherlands, and Redwood City, California, Feb. 27, 2024 -- QIAGEN today announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel...

Venlo, the Netherlands, Feb. 15, 2024 -- QIAGEN today announced two significant achievements in sustainability through recognitions by My Green Lab, a non-profit organization dedicated to...

Germantown, Maryland, and Venlo, the Netherlands, Jan. 08, 2024 -- QIAGEN today announced the U.S. Food and Drug Administration clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu...

Venlo, the Netherlands, Jan. 07, 2024 -- QIAGEN N.V. today announced a plan to return up to approximately $300 million to shareholders through a synthetic share repurchase that combines a direct...

Venlo, the Netherlands, Nov. 09, 2023 -- QIAGEN today announced the launch of three new kits for use on its QIAcuity systems and a major new software update designed to expand the portfolio of...